OOIR: Observatory of International Research

Papers

(The TQCC of Multiple Sclerosis Journal is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition	1275
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021	185
A smartphone sensor-based digital outcome assessment of multiple sclerosis	67
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres	46
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study	45
Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis	45
Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis	44
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension	41
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II	41
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network	41
Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms	40
Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis	40
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years	39
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results	39
MSVirtual 2020 – Poster Abstracts	38
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MO	37
The emerging role of artificial intelligence in multiple sclerosis imaging	37
Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression	35
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies	35
Childhood obesity and multiple sclerosis: A Mendelian randomization study	35
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic	34
Expansion of chronic lesions is linked to disease progression in relapsing–remitting multiple sclerosis patients	34
Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis	34
Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders	33
Serum neurofilament light in MS: The first true blood-based biomarker?	33

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis	33
Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS	32
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology	32
The timed 25-foot walk in a large cohort of multiple sclerosis patients	32
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis	32
The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis	32
ADEM after ChAdOx1 nCoV-19 vaccine: A case report	31
Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis	31
Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis	30
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis	29
Mediterranean diet is linked to less objective disability in multiple sclerosis	29
Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry	28
Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis	28
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation	28
Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis	28
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study	28
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments	27
Optic chiasm involvement in AQP-4 antibody–positive NMO and MOG antibody–associated disorder	26
Serum ceramide levels are altered in multiple sclerosis	25
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study	25
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study	25
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey	25
Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort	25
Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis	24
ECTRIMS 2021 – ePoster	24
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focuse	24
Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis	24
The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia	24
The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis	24
Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning	23
ACTRIMS Forum 2023 - Poster Presentations	23
Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis	23
Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES)	22
Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis	22
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors	22
Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses	22
Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis	21
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement	21
Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome	21
Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder	21
MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination	21
Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD	21
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years	21
Extended dosing of monoclonal antibodies in multiple sclerosis	21
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring	21
COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey	20
Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy	20
Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica	20
Staging and stratifying cognitive dysfunction in multiple sclerosis	20
Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis	20

A proposed new taxonomy of cognitive phenotypes in multiple sclerosis: The International Classification of Cognitive Disorders in MS (IC-CoDiMS)	20
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analys	20
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial	20
Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis	20
Ethical use of off-label disease-modifying therapies for multiple sclerosis	19
Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study	19
Brain structural and functional alterations in MOG antibody disease	19
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS	19
Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis	19
Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial	18
Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial	18
Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review	18
Performance validity in outpatients with multiple sclerosis and cognitive complaints	18
The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina	18
Pathways to cures for multiple sclerosis: A research roadmap	18
Atlas of MS 2020: Informing global policy change	18
Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance	17
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study	17
ECTRIMS 2022 – Poster	17
Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation	17
Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study	17
Leptomeningeal enhancement on post-contrast FLAIR images for early diagnosis of Susac syndrome	17
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies	17
Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis	17
Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis	16
Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis	16
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial	16
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data	16
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry	16
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society	16
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs	16
The SDMT is not information processing speed	16
Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI	16
Accurate classification of secondary progression in multiple sclerosis using a decision tree	16
Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis	15
Acute and chronic synaptic pathology in multiple sclerosis gray matter	15
Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care	15
Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry	15
Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis	15
Youth with multiple sclerosis have low levels of fitness	15
EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold	15
Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients	14
Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis	14
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?	14
CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event	14
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis	14
Identification of regulatory T cell molecules associated with severity of multiple sclerosis	14
The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis	14
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions	14
Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis	14
Enhancing diversity of clinical trial populations in multiple sclerosis	14
Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening	14
Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis	14
PRF1 mutation alters immune system activation, inflammation, and risk of autoimmunity	14
Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments	14
Cognition and disease characteristics in adult onset versus late onset multiple sclerosis	14
Physical exercise in multiple sclerosis is not just a symptomatic therapy: It has a disease-modifying effect—Yes	13
Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?	13
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial	13
Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States	13
Productivity loss among people with early multiple sclerosis: A Canadian study	13
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy	13
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis	13
Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging	13
ECTRIMS 2022 – ePoster	13
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis	13
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis	13
Cladribine and pregnancy in women with multiple sclerosis: The first cohort study	13
Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis	13
Body mass index as a predictor of MS activity and progression among participants in BENEFIT	13
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS	13
Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis	12
Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis	12
Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey	12
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study	12
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy)	12
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica	12
Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case–control study of the UK MS Register	12
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD	12
Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria	12

Changes in prognosis of the Danish multiple sclerosis population over time	12
Corpus callosum damage to account for cognitive, affective, and social-cognitive dysfunctions in multiple sclerosis: A model of callosal disconnection syndrome?	12
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study	12
Depression in multiple sclerosis across the adult lifespan	12
Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD	12
Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial	11
Recommendations for the use of propensity score methods in multiple sclerosis research	11
Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis	11
Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation	11
Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies	11
Exercise and the brain in multiple sclerosis	11
Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive–motor interference in persons with multiple sclerosis	11
Validation of the International MOGAD Panel proposed criteria	11
T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy	11
Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study	11
Cumulative effects of therapies on disability in relapsing multiple sclerosis	11
A higher burden of multiple sclerosis genetic risk confers an earlier onset	11
A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort stu	11
Polypharmacy and multiple sclerosis: A population-based study	11
Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis	11
Slowly expanding lesions are a marker of progressive MS – Yes	11
The expansion and severity of chronic MS lesions follows a periventricular gradient	10
An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis	10
A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression	10
Inverse association between Mediterranean diet and risk of multiple sclerosis	10
Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability	10
Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients	10
Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis	10
CSF extracellular vesicles and risk of disease activity after a first demyelinating event	10
Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study	10
Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease	10
Depression and multiple sclerosis: A bidirectional Mendelian randomisation study	10
Hypertension and hypertension severity in Hispanics/Latinx with MS	10
Altered brain network function during attention-modulated visual processing in multiple sclerosis	10
Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation	10
A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry	10
Epilepsy as a predictor of disease progression in multiple sclerosis	10
High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis	10
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS	10
Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses	10
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No	9
Gene–environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution	9
Prediction of multiple sclerosis outcomes when switching to ocrelizumab	9
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis	9
Risk of depression in multiple sclerosis across disease-modifying therapies	9
Safety of exercise training in multiple sclerosis: An updated systematic review and meta-analysis	9
Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder	9
Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study	9
Primary results of a phase-III, randomized controlled trial of the Behavioral Intervention for increasing Physical Activity in Multiple Sclerosis project	9
Slowly expanding lesions are a marker of progressive MS – No	9
A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?	9
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society	9
A new look at cognitive functioning in pediatric MS	9
An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis	9
Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis	9
Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability	9
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study	9
Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies	9
Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study	9
Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study	9
Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder	8
Clinical predictors of driving simulator performance in drivers with multiple sclerosis	8
A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database	8
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs	8
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab	8
Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI	8
Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women	8
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study	8
Mechanisms of central brain atrophy in multiple sclerosis	8
Machine learning classification of multiple sclerosis in children using optical coherence tomography	8
High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development	8
The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review	8
Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation	8
Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis	8
The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study	8
Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient	8
Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry	8
Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors	8
Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss	8
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials	8
Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients	8
Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal	8
Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis	8
Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis	8
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions	8
Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination	8
Risk factors for peripartum depression in women with multiple sclerosis	8
Unbiased examination of genome-wide human endogenous retrovirus transcripts in MS brain lesions	8
Paramagnetic rim lesions lead to pronounced diffuse periplaque white matter damage in multiple sclerosis	8
A comparison of clinical outcomes in PPMS in the INFORMS original trial data set	8
Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients	8